Literature DB >> 1797820

Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection.

J E Coutant1, P A Westmark, P A Nardella, S M Walter, R A Okerholm.   

Abstract

This work describes the methodology for the analysis of terfenadine and the acid metabolite of terfenadine in plasma using high-performance liquid chromatography. The use of solid-phase extraction allows the use of robotic or manual sample preparation for the efficient clean-up of terfenadine and terfenadine acid metabolite from plasma. Additional selectivity is obtained through the use of fluorescence detection. For terfenadine, the validated quantitation range of this method is 10.0-84.2 ng/ml with coefficients of variation of 5.7-30%. For terfenadine acid metabolite, the validated quantitation range of this method is 8.2-500 ng/ml with coefficients of variation of 4.1-24%.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797820     DOI: 10.1016/0378-4347(91)80208-t

Source DB:  PubMed          Journal:  J Chromatogr


  11 in total

Review 1.  Effects of H1 antihistamines on animal models of QTc prolongation.

Authors:  J Gras; J Llenas
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers.

Authors:  T Yang; C Prakash; D M Roden; D J Snyders
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

3.  Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model.

Authors:  T Usui; A Sugiyama; Y Ishida; Y Satoh; Y Sasaki; K Hashimoto
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

4.  Quantification of the transporter substrate fexofenadine in cell lysates by liquid chromatography/tandem mass spectrometry.

Authors:  Colleen A Flynn; Yazen Alnouti; Gregory A Reed
Journal:  Rapid Commun Mass Spectrom       Date:  2011-08-30       Impact factor: 2.419

5.  MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

Authors:  Siegfried Drescher; Elke Schaeffeler; Monika Hitzl; Ute Hofmann; Matthias Schwab; Ulrich Brinkmann; Michel Eichelbaum; Martin F Fromm
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

6.  Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.

Authors:  Parul Gor; Yazen Alnouti; Gregory A Reed
Journal:  J Pharm Biomed Anal       Date:  2011-04-09       Impact factor: 3.935

7.  Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine.

Authors:  P K Honig; D C Wortham; K Zamani; D P Conner; J C Mullin; L R Cantilena
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Transport characteristics of fexofenadine in the Caco-2 cell model.

Authors:  Niclas Petri; Christer Tannergren; David Rungstad; Hans Lennernäs
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

9.  Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography.

Authors:  K Yanai; J H Ryu; T Watanabe; R Iwata; T Ido; Y Sawai; K Ito; M Itoh
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

10.  Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates.

Authors:  Melonie L Stanton; Melanie S Joy; Reginald F Frye
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-12-24       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.